Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation
NCT03758677
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Non Small Cell Lung Cancer
Interventions
DRUG:
Apatinib
Sponsor
The First Hospital of Jilin University